21:59 , Jul 11, 2019 |  BC Innovations  |  Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
00:45 , Jun 5, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: May 2019

New Therapeutic Targets and Biomarkers: May 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during May. Therapeutic targets are defined as any protein, gene or other molecule...
20:53 , May 20, 2019 |  BC Innovations  |  Distillery Therapeutics

Trivalent vaccination confers protection against three equine encephalitis viruses

DISEASE CATEGORY: Infectious disease INDICATION: Encephalitis Cell culture, mouse and macaque studies suggest a trivalent vaccine based on multiple proteins from Eastern, Western and Venezuelan equine encephalitis viruses could help prevent encephalitis caused by the...
22:34 , May 14, 2019 |  BC Extra  |  Clinical News

May 14 Clinical Quick Takes: Myovant, Solid, Minerva, Modus, Zealand

Myovant tumbles after Phase III uterine fibroid data  Myovant Sciences Ltd. (NYSE:MYOV) lost $4.39 (25%) to $12.83 Tuesday despite reporting that relugolix (TAK-385) met the primary endpoint of a better response rate than placebo in...
12:35 , May 8, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: April 2019

New Therapeutic Targets and Biomarkers: April 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during April. Therapeutic targets are defined as any protein, gene or other molecule...
20:14 , Apr 30, 2019 |  BC Innovations  |  Distillery Therapeutics

GP1BB identified as NASH target

DISEASE CATEGORY: Hepatic INDICATION: Non-alcoholic steatohepatitis (NASH) Mouse studies suggest inhibiting GP1BB could help treat NASH. In a mouse model of NASH, a Fab fragment from an anti-GP1BB mAb decreased steatosis, liver damage and fibrosis,...
22:50 , Apr 22, 2019 |  BC Innovations  |  Distillery Therapeutics

Viral gH, gL and gp42 as new Epstein-Barr virus vaccine targets

DISEASE CATEGORY: Infectious disease INDICATION: Epstein-Barr virus (EBV) Cell culture, mouse and macaque studies suggest vaccines based on EBV gH, gL and gp42 could help prevent EBV infection. The vaccines consist of self-assembling protein nanoparticles...
03:36 , Apr 18, 2019 |  BC Extra  |  Financial News

Hookipa raises $84M in IPO

Hookipa raised $84 million in an IPO on NASDAQ late Wednesday, pricing at the bottom of its range and selling fewer shares than the company had hoped. Hookipa Pharma Inc. (NASDAQ:HOOK) sold 6 million shares...
23:22 , Mar 28, 2019 |  BioCentury  |  Finance

Polyneuron’s surgical strike

Polyneuron’s broad platform and method of directly targeting autoantibodies rather than B cells for autoimmune diseases prompted Sofinnova Partners and New Enterprise Associates to invest in the Basel-based company’s CHF22.5 million ($22.6 million) series A...
08:18 , Mar 28, 2019 |  BC Extra  |  Financial News

Polyneuron raises $22.6M series A to bring neuropathy therapy into clinic

Backed by Sofinnova Partners and New Enterprise Associates, Polyneuron raised CHF22.5M ($22.6 million) in a series A round to bring its anti-MAG neuropathy therapy, PN-1007, into the clinic. Polyneuron Pharmaceuticals AG (Basel, Switzerland) is developing...